Evogene Ltd. (TLV:EVGN)
Israel · Delayed Price · Currency is ILS · Price in ILA 113.20
-0.20 (-0.18%)
Oct 23, 2026, 1:44 PM IDT
Evogene Revenue
Evogene had revenue of $347.00K USD in the quarter ending June 30, 2026, a decrease of -35.02%. This brings the company's total for the last twelve months to $1.31M, down -78.78% year-over-year. In the year 2025, Evogene had annual revenue of $3.85M, down -30.91%. That makes Evogene the 42,808th largest company in the world by revenue and 426th in Israel.
Revenue (ttm)
$1.31M
Revenue Growth
-78.78%
P/S Ratio
3.63
Revenue / Employee
$25.13K
Employees
52
Market Cap
17.89M ILS
Revenue by Segment
Fiscal year ended Dec 31, 2025 See the full Evogene breakdown
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 3.85M | -1.72M | -30.91% |
| Dec 31, 2024 | 5.58M | -63.00K | -1.12% |
| Dec 31, 2023 | 5.64M | 3.97M | 236.72% |
| Dec 31, 2022 | 1.68M | 745.00K | 80.11% |
| Dec 31, 2021 | 930.00K | -110.00K | -10.58% |
| Dec 31, 2020 | 1.04M | 287.00K | 38.11% |
| Dec 31, 2019 | 753.00K | -994.00K | -56.90% |
| Dec 31, 2018 | 1.75M | -1.63M | -48.33% |
| Dec 31, 2017 | 3.38M | -3.16M | -48.30% |
| Dec 31, 2016 | 6.54M | -4.59M | -41.23% |
| Dec 31, 2015 | 11.13M | -3.38M | -23.31% |
| Dec 31, 2014 | 14.51M | -3.07M | -17.46% |
| Dec 31, 2013 | 17.58M | 509.00K | 2.98% |
| Dec 31, 2012 | 17.07M | 2.17M | 14.57% |
| Dec 31, 2011 | 14.90M | 2.34M | 18.61% |
| Dec 31, 2010 | 12.56M | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. It does not take any expenses into account and is therefore different from profits.
Evogene News
- 3 days ago - Evogene to Participate in U.S. East Coast AI Drug Discovery Roadshow Organized by the Israel Export Institute and TradeIL - PRNewsWire
- 16 days ago - Evogene (EVGN) Forms Strategic Partnership to Resolve Disputes and Stabilize Operations - GuruFocus
- 16 days ago - Evogene announces cooperation agreement with Pure Capital Group - TheFly
- 17 days ago - Evogene and Pure Capital Group Reach Cooperation Agreement to Resolve Differences and Reconstitute Board of Directors - PRNewsWire
- 23 days ago - Evogene Gets 180-day Nasdaq Extension To Regain Compliance - Nasdaq
- 23 days ago - Evogene receives non-compliance letter from Nasdaq - TheFly
- 23 days ago - Evogene Reports Nasdaq Grants Additional 180-Day Period to Regain Minimum Bid Price Compliance - PRNewsWire
- 7 weeks ago - Evogene responds to latest communication from L.I.A. Pure Capital, Invest-Pro - TheFly